BPC 157 for Acute Hamstring Muscle Strain Repair
A randomized, double-blind, placebo-controlled Phase 2 trial testing whether BPC-157 speeds structural healing and functional recovery after an acute grade II hamstring muscle strain, on top of standard rehabilitation. This is the first registered controlled human trial of BPC-157 for a specific musculoskeletal injury — see the BPC-157 Evidence Profile for the full picture, including why human data on this compound has been so limited until now.
BPC-157 has a large preclinical literature proposing tissue-repair and angiogenic effects, but — per the Evidence Profile — essentially no controlled human trial data existed before this. Acute hamstring strains are common in sport, often cause prolonged time away, and carry a meaningful re-injury risk, making them a practical, measurable test case for a tissue-repair compound.
Randomized 1:1, double-blind, placebo-controlled, Phase 2
Adults with an acute grade II hamstring strain confirmed by MRI. Enrollment: 120 (estimated)
Subcutaneous BPC-157 or matching placebo, once daily for 14 days, alongside a standardised rehabilitation protocol supervised by study physiotherapists
Co-primary endpoints: time to return to unrestricted sport, and change in MRI-assessed injury volume at Day 14. Clinical assessments continue at Days 3, 7, 14, 28, and 56, with a further follow-up at 3 months post-return-to-play to monitor recurrence. An independent Data and Safety Monitoring Committee reviews unblinded safety data at set intervals.
What the registry says
Status: Recruiting, as of the last verified date. Started February 2026. Estimated primary completion February 2027, full completion February 2028.
This is a protocol and a plan — it describes what will be measured, not what was found.
What published research has found
Nothing yet. No results, published or registry-posted, exist for this trial at the time of writing.
What This Trial Tells Us
- Researchers consider BPC-157's preclinical signal strong enough to justify a controlled human trial for this specific injury.
- There is now a real, structured attempt underway to generate the kind of controlled human data the Evidence Profile flags as missing.
What It Does NOT Tell Us
- Whether BPC-157 actually speeds hamstring recovery — that's exactly what this trial is trying to find out, not something it has shown.
- A trial being registered and recruiting is not evidence of efficacy, regardless of how promising the underlying science sounds.
- Even once complete, one trial in one injury type won't establish BPC-157's effects generally — it will answer this specific question, in this specific population.